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Although warfarin has been the "king" of oral anticoagulation for the past few decades, its reign is now jeopardized by the recent marketing in Canada of 3 new oral anticoagulants: dabigatran (Pradaxa*), rivaroxaban (Xarelto) and apixaban (Eliquis). [1] [2] [3] The recent availability of these 3 new oral anticoagulants is challenging for health professionals, as they differ in many ways from warfarin and each other, including in their mechanism of action, pharmacokinetics, drug interaction profile, monitoring and dosage adjustment requirements. Despite their widespread use in the community and hospitals, many practising clinicians remain unfamiliar with how to use these medications safely. 4 This article provides a practice tool to assist health professionals to effectively use these medications and monitor their patients. For ease of use and retrieval of the specific characteristics of these new anticoagulants, the information has been summarized and presented in tables. A total of 5 comparative tables are featured: 1) pharmacology and pharmacokinetic properties, 2) indications and dosages, 3) significant drug interactions, 4) recommendations for switching anticoagulants and 5) management in the perioperative setting. A brief discussion on laboratory monitoring and reversing the activity of these drugs is also included.
To build these tables, the product monographs of the new oral anticoagulants were reviewed thoroughly and Drugdex (from Micromedex), LexiComp and Lexi-Interact databases were consulted. A literature search was conducted using OVID MEDLINE and an internal citation database of pharmacy journals (AskSam) to identify related articles. The following search terms (Medical Subject Headings and key words) were used: apixaban, dabigatran, rivaroxaban, review, switching, perioperative care, perioperative setting and hemorrhage. The literature search did not include randomized clinical trials and should not be viewed as a systematic review, as the goal was to collect key and practical prescribing information about the new oral anticoagulants, rather than assess them for their comparative efficacy and safety.
Pharmacology and pharmacokinetic properties
The new oral anticoagulants differ in their pharmacology and pharmacokinetics (Table  1) . Although their onset of action and half-life are quite similar, other properties such as their respective mechanism of action, bioavailability, metabolism and clearance are different. Clinicians should be aware of these differences to ensure that each drug is used properly. Table 2 features all indications and dosages approved by Health Canada, extracted from the most recent product monographs available at the time this article was prepared. Currently, rivaroxaban is the only new oral anticoagulant approved for the treatment of deep vein thrombosis and pulmonary embolism. However, this may change in the future, as many trials are currently being conducted for the above indication as well as others, which may lead to further approved indications from Health Canada.
Indications and dosages
With its low renal elimination, apixaban can be considered the preferred agent for elderly *Pradaxa was originally named Pradax in Canada: the name was recently changed to align the product name with the United States and European countries (personal communication with Boehringer Ingelheim, October 3, 2012).
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patients or those with decreased renal function. It can be administered, although with caution, to patients with a creatinine clearance as low as 15 mL/min as opposed to dabigatran and rivaroxaban, which should not be administered to patients with a creatinine clearance less than 30 mL/min.
Significant drug interactions
Although the new oral anticoagulants are viewed as less prone to drug interactions compared with warfarin, they are still implicated in many interactions, which may require special attention and monitoring. They do not significantly induce or inhibit metabolism of other drugs; rather, it is the other drugs that can alter their anticoagulant activity. Table 3 features the most important pharmacokinetic (i.e., change of at least 50% in the anticoagulant plasma concentrations) and pharmacodynamic interactions. Many of the drug interactions quoted in the table are serious enough that concomitant therapy should be avoided (interacting drugs are identified by an asterisk). For the less serious interactions, the reader should refer to more specialized references, as options for their management differ depending on the indication for the drug and the patient status. The options most quoted are 1) changing of the anticoagulant dose, 2) spacing the time between the administration of the 2 interacting drugs and 3) exercising more caution when the interacting drugs are administered together. [1] [2] [3] 7, 8, 11 Recommendations for switching anticoagulants Table 4 summarizes the information on the management of patients who need to switch from a parenteral anticoagulant (heparin or a lowmolecular-weight heparin) or warfarin to one of the new oral anticoagulants and vice versa. The manufacturers of the new oral anticoagulants offer recommendations to ease these transitions; these recommendations are identified in the table 
Prevention of stroke and systemic embolism in patients with AFib:
150 mg twice daily.
In the elderly ≥80 years: 110 mg twice daily.
20 mg once daily. 5 mg twice daily. Reduce to 2.5 mg twice daily if at least 2 of the 3 following factors:
Treatment of DVT, pulmonary embolism and prevention of recurrences:
15 mg twice daily × 3 weeks, followed by 20 mg once daily. Duration of therapy is 3-6 months or longer; refer to Chest Guidelines 2012.
Dosage in renal failure

Prevention of VTE in orthopedic surgery:
For CrCl 30-50 mL/min: 75 mg 1-4 hours after surgery followed by 150 mg once daily thereafter. For CrCl <30 mL/min: Do NOT use.
For CrCl 30-49 mL/min: 10 mg once daily. For CrCl <30 mL/min: Do NOT use.
For CrCl ≥30 mL/min: 2.5 mg twice daily (no dosage adjustment). For CrCl 15-29 mL/min: Use with caution. For CrCl <15 mL/min: Do NOT use.
Prevention of stroke and systemic embolism in patients with AFib :
For 
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as MPM (manufacturer's product monograph). [1] [2] [3] However, independent authors have also published their own recommendations based on their clinical experience or opinions; these recommendations are also featured in the table as LIT (the medical literature). 4 As proposed methods from MPM and LIT may differ slightly, the final decision will depend on each patient case and the level of comfort of the prescriber.
Recommendations may change as clinical experience is gained with these new drugs. Note that dabigatran and rivaroxaban should only be administered to patients with a creatinine clearance of 30 mL/min and higher. However, if the renal function of a patient deteriorates and falls below the 30 mL/min range, some authors have offered a method to switch these patients from dabigatran or rivaroxaban to warfarin. Table 5 summarizes the information on the management of patients who are receiving a new oral anticoagulant and are scheduled for a surgery. Depending on the type of surgery (i.e., major or minor) and the associated risk Anticoagulants include argatroban, bivalirudin, danaparoid, fondaparinux, heparin, lepirudin, low-molecular-weight heparins (dalteparin, enoxaparin, nadroparin, tinzaparin) and warfarin. Note that when switching from one of the new oral anticoagulants to warfarin, a short period of concomitant use is acceptable to allow time to achieve therapeutic international normalized ratio. g Thrombolytics include alteplase, reteplase and tenecteplase. Note: (above list of drug interactions is not exhaustive) 1) P-glycoprotein (P-gp) is a transporter system located in the epithelial cells of the intestine (enterocytes). As the drug molecules diffuse through the enterocytes, P-gp picks up the drug molecules and carries them back to the luminal side of the cell, preventing them from reaching the circulation. Therefore, when a drug inhibits the P-gp pump system, it increases the systemic availability of a P-gp-sensitive drug, with a resultant enhanced activity/toxicity. Conversely, if a drug induces the P-gp system, less of the drug reaches the systemic circulation and therefore its activity will be decreased.
Management in the perioperative setting
2) CYP 450 3A4 is an enzyme located in the liver, which metabolizes a wide variety of drugs. Inhibition will decrease the metabolism of drugs that depend on this enzyme for their elimination, thereby increasing the activity/toxicity of these agents. Conversely, if a drug induces this enzyme, the drugs that depend on this enzyme for their elimination will have a higher rate of elimination and their activity will be diminished. PRaCtiCe tOOL LIT, the medical literature 4, 13 ; MPM, manufacturer's product monograph; NA, not available. *As an example, if it says "Last dose on day -2, " it should be interpreted as last dose of anticoagulant given on day -2, with day 0 being the day of the surgery. †As the new oral anticoagulants have a fast onset and offset of action, bridging anticoagulation during the perioperative period with a lowmolecular-weight heparin (LMWH) may not be needed. However, in some patients in whom oral medication cannot be resumed quickly after the surgery (e.g., bowel paralysis), especially in patients at moderate to high risk of thromboembolism, bridging anticoagulation with an LMWH may be desirable. 13 In these cases, a specialized service (e.g., thrombosis, hematology or internal medicine service) should be consulted. ‡The product monograph from the manufacturer provides only this general statement.
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of bleeding (i.e., high or low), the period for going off the anticoagulant during the perioperative period will vary. For example, major cardiovascular surgery, orthopedic surgery, urologic surgery and surgeries lasting 45 minutes and longer are considered high bleeding risk. Nonmajor procedures lasting less than 45 minutes, such as cholecystectomy, simple dental extractions or carpal tunnel repair, are classified as low bleeding risk. 13 The manufacturers of the new oral anticoagulants offer recommendations for the perioperative period; as in the previous table, these recommendations are identified in the table as MPM (manufacturer's product monograph). 1-3 However, independent authors have also published their own recommendations based on their clinical experience and drug pharmacokinetics; these recommendations are also featured in the table as LIT (the medical literature). 4, 13 As proposed methods from product monographs and the medical literature may differ slightly, the final decision will depend on each patient, surgeon and the surgery bleeding risk. As the renal function of a patient can deteriorate and fall below 30 mL/min before surgery, some recommendations for managing patients on dabigatran and rivaroxaban in this setting have been suggested.
Laboratory monitoring and reversal of anticoagulant activity
Dabigatran, rivaroxaban and apixaban do not require routine laboratory monitoring, as their stable pharmacokinetic properties provide predictable and consistent anticoagulant activity. In addition, none of the standard coagulation tests constitutes a sensitive or accurate measure of their therapeutic activity. 14 Although the lack of routine laboratory monitoring is viewed as an advantage, an assessment of the drug concentration or residual activity could be helpful in emergency situations such as hemorrhage, urgent surgery or overdose, as well as ensuring compliance with therapy. 14, 15 Presently, laboratory investigations are being conducted to address this issue; however, final recommendations are pending, as some of the studied coagulation tests may not be available in each institution or laboratory. 15, 16 In contrast to warfarin, there is no specific antidote for neutralizing the activity of these new oral anticoagulants. 16, 17 Minor bleeding (e.g., epistaxis, menorrhagia, ecchymosis) can be managed by holding the anticoagulant for 1 or more doses. 4 In the case of a major bleed and/ or care of a critical patient, a specialized service (e.g., thrombosis, hematology, critical care or internal medicine service) should be consulted, as management is still evolving; a case-by-case approach is recommended and may include the use of restricted and expensive blood products (e.g., recombinant factor VII, human prothrombin complex concentrates, etc.). 4, [16] [17] [18] For overdose situations, activated charcoal administered early after the ingestion has been suggested, based on an in vitro study with dabigatran. 18, 19 Also, in the case of dabigatran, its pharmacokinetic properties (low protein binding and renal excretion) allow drug removal by hemodialysis, where a 2-hour session may remove up to 62% of the drug. 20 Reversing the anticoagulant activity of these new drugs is still at an experimental stage, and further studies are needed before formal recommendations can be made.
To prevent excessive anticoagulation and increased risk of bleeding, the new oral anticoagulants should not be administered to patients with a creatinine clearance below 30 mL/ min for dabigatran and rivaroxaban and below 15 mL/min for apixaban. In these situations, drug accumulation and risk of toxicity may exceed the benefits. The renal function of patients who are currently on these drugs should be monitored regularly. 1 
